Charting a New Course
We’re in a golden age of technology-driven healthcare that’s changing how people experience medicine. From the activation of non-episodic health data to the mobilization of personal health records across different ecosystems, new technological advances are challenging the status quo for standard of care. In "Charting a New Course," we're highlighting thought leaders and exploring unique perspectives in the healthcare industry. Join us for compelling conversations with people who are re-thinking how human beings can thrive within a new, better, digital healthcare system. This is about imagining what’s possible. No topic is off limits.
Charting a New Course
Digital Therapeutics… Don’t Call It a Comeback!
Is DTx ready for a comeback? Earlier this month, the Centers for Medicare and Medicaid Services (CMS) fee schedule called for reimbursement of digital therapeutics. In February of this year, Happify Health, which became Twill, was acquired by Dario Health. Then, in April, Curio won FDA approval for its postpartum depression digital therapeutic, and for Otsuka’s digital treatment for depression. Perhaps no industry went from “hero to zero and possibly back to hero…” in the post-Covid world faster than the digital therapeutics industry.
An industry plagued by claims of poor outcomes and faulty data has seen a renaissance in 2024. In the next two episodes, Brendon Kelly and Dr. Zucker (a long-time veteran and advocate of the DTX space) walk us through the state of the union for digital therapeutics.